Drug treatments for maintaining remission in Crohn's disease: A lifetime cost-utility analysis

PharmacoEconomics

Volumn 11, Issue 5, 1997, Pages 444-453

  Trallori, Giacomo ^a   Messori, Andrea ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MESALAZINE;

ARTICLE; CONTROLLED STUDY; COST UTILITY ANALYSIS; CROHN DISEASE; DRUG COST; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION;

EID: 0030975507     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199711050-00006     Document Type: Article

References (37)

1. Messori A, Brignola C, Trallori G, et al. Effectiveness of 5-aminosalicylic acid (5-ASA) for maintaining remission in patients with Crohn's disease: a meta-analysis. Am J Gastroenterol 1994; 89: 692-8
2. Caprilli R, Andreoli A, Capurso L, et al. 5-ASA in the prevention of Crohn's disease postoperative recurrence: an interim report of the Italian Study Group of the Colon (GISC) [abstract]. Gastroenterology 1992; 102: A601
3. Gendre JP, Mary JY, Florent C, et al. Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. Gastroenterology 1993; 104: 435-9
4. IMSG (International Mesalazine Study Group). Coated oral 5-aminosalicylic acid versus placebo in maintaining remission of inactive Crohn's disease. Aliment Pharmacol Ther 1990; 4: 428-37
5. Prantera C, Pallone F, Brunetti G, et al. Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease. Gastroenterology 1992; 103: 363-8
6. Hay J, Hay A. Inflammatory bowel disease: cost of illness. J Clin Gastroenterol 1992; 14: 309-17
7. Hay J, Hay A. Inflammatory bowel disease: medical cost algorithms. Clin Gastroenterol 1992; 14: 318-27
8. Pera A, Rocca H. Le malattie inflammatorie croniche intestinali: profili di diagnosi e terapia. Milano: EDRA srl, 1995
9. Binder V, Hendriksen C, Kreiner S. Prognosis in Crohn's disease based on results from a regional patient group from the county of Copenhagen. Gut 1985; 26: 146-50
10. Brignola C, Cottone M, Pera A, et al. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Gastroenterology 1995; 108: 345-9
11. Caprilli R, Andreoli A, Capurso L, et al. Oral mesalazine for the prevention of postoperative recurrence of Crohn's disease. Aliment Pharmacol Ther 1994; 8: 35-43
12. Cooke WT, Mallas E, Prior P, et al. Crohn's disease: course, treatment and longterm prognosis. Q J Med 1980; 195: 365-84
13. Depew WT, Medeiros J, Beck IT, et al. Clinical presentation and course of Crohn's disease in southeastern Ontario. Can J Gastroenterol 1988; 2: 107-16
14. Farmer RG, Whelan G, Fazio WW. Long term follow-up of patients with Crohn's disease: relationship between the clinical pattern and prognosis. Gastroenterology 1985; 88: 1818-25
15. Fiasse R, Fontaine F, Vanheuverzwyn R. Prevention of Crohn's disease recurrences after intestinal resection with Eudragit-L-coated 5-aminosalicylic acid: preliminary results of a 1-year double-blind placebo-controlled study [abstract]. Gastroenterology 1991; 100: A208
16. Florent C, Cortot A, Modigliani R, et al. Placebo-controlled trial of Claversal in the prevention of early endoscopic relapse after curative resection for Crohn's disease [abstract]. Gastroenterology 1992; 102: A623
17. Harper PH, Fazio WW, Lavery IC, et al. The long term outcome in Crohn's disease. Dis Colon Rectum 1987; 30: 174-9
18. Heimann TM, Greenstein AJ, Lewis B, et al. Prediction of early symptomatic recurrence after intestinal resections in Crohn's disease. Ann Surg 1993; 28: 294-9
19. Krause U, Ejerbald S, Bergman L. Crohn's disease. A long term study of the clinical course in 186 patients. Scand J Gastroenterol 1985; 20: 516-24
20. Lindhagen T, Ekelund G, Leandoer L, et al. Pre- and post-operative complications in Crohn's disease with special references to duration of pre-operative disease history. Scand J Gastroenterol 1984; 19: 194-203
21. Lochs H, Prainer CH, Westphal G, et al. Course and clinical features of Crohn's disease. Dtsch Med Wochenschr 1985; 110: 1031-34
22. McLeod RS, Wolff BG, Steinhart H, et al. Delayed recurrence following surgery for Crohn's disease [abstract]. Gastroenterology 1994; 106: A733
23. Okada M, Yao T, Fichigami T, et al. Anatomical involvement and clinical fealures in 91 Japanese patients with Crohn's disease. J Clin Gastroenterol 1987; 9: 165-71
24. Olaison G, Smedh K, Sjodahl R. Natural course of Crohn's disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms. Gut 1992; 33: 331-5
25. Rutgeerts P, Geboes K, Vantrappen G, et al. Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. Gut 1984; 25: 665-72
26. Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990; 99: 956-63
27. Testa MA, Simonson DC. Assessment of quality-of-life outcomes. N Engl J Med 1996; 334: 835-40
28. DiComite L, Chiassino G. Elementi di demografia. Bari: Cacucci Editore 1995: 56-61
29. Tapinos G. Elementi di demografia. Milano: EGEA Spa, 1994: 186
30. Robinson R. Cost-effectiveness analysis. BMJ 1993; 307: 793-5
31. Mark DB, Hlatky MA, Califf RM, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995; 332: 1418-24
32. Mark DB. Economic analysis methods and end-points. In: Califf RM, Mark DB, Wagner GS, editors. Acute coronary care in the thrombolytic era. St Louis: Mosby, 1995: 167-82
33. Schulman K, Lynn LA, Glick HA, et al. Cost-effectiveness of low-dose zidovudine therapy for asymptomatic HIV infection. Ann Intern Med 1991; 114: 798-802
34. Messori A, Becagli P, Trippoli S, et al. Cost-effectiveness of adjuvant chemotherapy with cyclophosphamide + methotrexate + fluorouracil in patients with node-positive breast cancer. Eur J Clin Pharmacol 1996; 51: 111-6
35. Wong JB, Koff RS, Tinè F, et al. Cost-effectiveness of interferon-alpha2b treatment for hepatitis B-e-antigen-positive chronic hepatitis B. Ann Intern Med 1995; 122: 664-75
36. Etchanson J, Petz L, Keeler E, et al. The cost effectiveness of preoperative autologuus blood donations. N Engl J Med 1995; 332: 719-24.
37. Weeks JC, Tierney MR, Weinstein MC. Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl J Med 1991; 325: 81-6